Search results
Results From The WOW.Com Content Network
DOTA is derived from the macrocycle known as cyclen.The four secondary amine groups are modified by replacement of the N-H centers with N-CH 2 CO 2 H groups. The resulting aminopolycarboxylic acid, upon ionization of the carboxylic acid groups, is a high affinity chelating agent for di- and trivalent cations.
Ethylenediaminetetraacetic acid (EDTA), also called EDTA acid, is an aminopolycarboxylic acid with the formula [CH 2 N(CH 2 CO 2 H) 2] 2. This white, slightly water-soluble solid is widely used to bind to iron (Fe 2+ /Fe 3+) and calcium ions (Ca 2+), forming water-soluble complexes even at neutral pH. It is thus used to dissolve Fe- and Ca ...
Chelation therapy is a medical procedure that involves the administration of chelating agents to remove heavy metals from the body. [1] Chelation therapy has a long history of use in clinical toxicology [2] and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks, including the mobilization of ...
Sodium calcium edetate is in the chelating agent family of medication. [3] It is a salt of edetate with two sodium atoms and one calcium atom. [4] It works by binding to a number of heavy metals, which renders them almost inert and allows them to leave the body in the urine.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Chelation in the intestinal tract is a cause of numerous interactions between drugs and metal ions (also known as "minerals" in nutrition). As examples, antibiotic drugs of the tetracycline and quinolone families are chelators of Fe 2+ , Ca 2+ , and Mg 2+ ions.
Edotreotide (USAN, also known as (DOTA 0-Phe 1-Tyr 3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. [3] When used therapeutically it is an example of peptide receptor radionuclide therapy.
The US Food and Drug Administration (FDA) approved 177 Lu dotatate based primarily on evidence from one clinical trial, NETTER-1 of 229 participants with somatostatin-receptor positive midgut GEP-NETs. [15] Enrolled participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. [15]